NC

Nicholas Company Portfolio holdings

AUM $5.47B Turnover 6.8%
1-Year Est. Return 16.96%
This Fund
S&P 500
This Quarter Est. Return
+4.79%
1 Year Est. Return
+16.96%
3 Year Est. Return
+65.72%
5 Year Est. Return
+94.16%
10 Year Est. Return
+404.17%
AUM
$4.21B
AUM Growth
+$64.6M
Cap. Flow
-$99.3M
Cap. Flow %
-2.36%
Top 10 Hldgs %
30.14%
Holding
265
New
11
Increased
89
Reduced
79
Closed
19
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.8 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$36.1M
2
ADT icon
ADT Corp
ADT
+$34.9M
3
PFE icon
Pfizer
PFE
+$27.7M
4
CB icon
Chubb
CB
+$19.3M
5
JCI icon
Johnson Controls International
JCI
+$15.1M

Top Sells

Rank Stock Value
1
LO
LORILLARD INC COM STK
LO
+$79.3M
2
MCRS
MICROS SYSTEMS INC
MCRS
+$73.6M
3
MSI icon
Motorola Solutions
MSI
+$51M
4
BHC icon
Bausch Health
BHC
+$23.5M
5
DTV
DIRECTV COM STK (DE)
DTV
+$15.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.03%
2 Consumer Discretionary 15.41%
3 Industrials 15.12%
4 Financials 11.91%
5 Technology 8.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
WBA icon
1
DELISTED
Walgreens Boots Alliance
WBA
$173M 4.11%
2,335,615
+350
+0% +$24.4K
2013 Q2
4 quarters
BHC icon
2
Bausch Health
BHC
$2.2B
$168M 3.98%
1,328,220
-184,310
-12% -$23.5M
2013 Q2
4 quarters
AMG icon
3
Affiliated Managers Group
AMG
$9.62B
$139M 3.31%
678,435
– –
2013 Q2
4 quarters
GILD icon
4
Gilead Sciences
GILD
$190B
$138M 3.29%
1,670,135
+55,180
+3% +$4.3M
2013 Q2
4 quarters
ORLY icon
5
O'Reilly Automotive
ORLY
$70.1B
$115M 2.72%
11,405,010
– –
2013 Q2
4 quarters
TMO icon
6
Thermo Fisher Scientific
TMO
$249B
$114M 2.71%
965,976
-375
-0% -$44.1K
2013 Q2
4 quarters
SNA icon
7
Snap-on
SNA
$18.8B
$112M 2.67%
946,850
-295
-0% -$34.1K
2013 Q2
4 quarters
AON icon
8
Aon
AON
$58.4B
$111M 2.65%
1,236,220
– –
2013 Q2
4 quarters
MSFT icon
9
Microsoft
MSFT
$3.96T
$101M 2.41%
2,430,050
+7,900
+0.3% +$320K
2013 Q2
4 quarters
CBRE icon
10
CBRE Group
CBRE
$37.3B
$96.4M 2.29%
3,008,715
-10,300
-0.3% -$297K
2013 Q2
4 quarters
KMI icon
11
Kinder Morgan
KMI
$74.3B
$92.4M 2.2%
2,548,765
+51,650
+2% +$1.74M
2013 Q2
4 quarters
BALL icon
12
Ball Corp
BALL
$16B
$92.4M 2.2%
2,948,872
– –
2013 Q2
4 quarters
DVA icon
13
DaVita
DVA
$11.5B
$86.3M 2.05%
1,193,598
-3,800
-0.3% -$264K
2013 Q2
4 quarters
TGNA icon
14
DELISTED
TEGNA Inc
TGNA
$85.7M 2.04%
5,232,454
+311,516
+6% +$4.57M
2013 Q2
4 quarters
LKQ icon
15
LKQ Corp
LKQ
$5.52B
$84.2M 2%
3,153,423
+64,740
+2% +$1.79M
2013 Q2
4 quarters
GWW icon
16
W.W. Grainger
GWW
$62.7B
$75M 1.78%
295,070
+600
+0.2% +$153K
2013 Q2
4 quarters
PII icon
17
Polaris
PII
$2.88B
$73.8M 1.75%
566,979
-61,695
-10% -$8.17M
2013 Q2
4 quarters
KMR
18
DELISTED
KINDER MORGAN MANAGEMENT LLC
KMR
$72.1M 1.71%
943,197
+647
+0.1% +$45.9K
2013 Q2
4 quarters
ATR icon
19
AptarGroup
ATR
$7.65B
$70.7M 1.68%
1,055,260
-240
-0% -$16K
2013 Q2
4 quarters
JCI icon
20
Johnson Controls International
JCI
$92.3B
$70.5M 1.68%
1,348,594
+304,010
+29% +$15.1M
2013 Q4
2 quarters
CPRT icon
21
Copart
CPRT
$24.3B
$69.6M 1.65%
15,492,680
– –
2013 Q2
4 quarters
ORCL icon
22
Oracle
ORCL
$396B
$66.6M 1.58%
1,642,765
+2,625
+0.2% +$108K
2013 Q4
2 quarters
CB icon
23
Chubb
CB
$135B
$64.8M 1.54%
625,310
+188,350
+43% +$19.3M
2014 Q1
1 quarter
PFE icon
24
Pfizer
PFE
$166B
$63.9M 1.52%
2,270,558
+971,993
+75% +$27.7M
2013 Q2
4 quarters
COV
25
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$62.4M 1.48%
691,815
-5,500
-0.8% -$411K
2013 Q2
4 quarters
1
2 3 4 5

Similar funds

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return

Nicholas Company's Q2 2014 Portfolio in Review

As of Q2 2014, Nicholas Company held 265 positions worth $4.21B, up 1.6% from $4.14B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Nicholas Company's Q2 2014 filing shows 11 new, 89 increased, 79 reduced and 19 closed positions. Its largest new stake was Celgene Corp: 474,120 shares worth $40.7M. The largest sale was LORILLARD INC COM STK, an estimated $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Industrials.

  • Nicholas Company's largest Q2 2014 buy was Celgene Corp: 474,120 shares worth $40.7M.
  • Nicholas Company added most to Pfizer in Q2 2014, an estimated $27.7M increase.
  • Nicholas Company's biggest Q2 2014 reduction was Bausch Health, cutting an estimated $23.5M.
  • Nicholas Company fully exited LORILLARD INC COM STK in Q2 2014, selling an estimated $79.3M.
  • Nicholas Company's ten largest holdings make up 30% of its $4.21B portfolio in Q2 2014.
  • Nicholas Company opened 11 new positions and closed 19 in Q2 2014.
  • Nicholas Company's portfolio value rose 1.6% quarter-over-quarter to $4.21B.

Based on Nicholas Company's 13F filing for Q2 2014, filed 14 Aug 2014.